Applied Pharmaceutical Innovation (API) announces the creation of a team with researchers from Nova Scotia universities for the discovery of antiviral drugs against SARS-CoV-2 and RNA viruses

Through this academic and industrial collaboration, the partners will create a rich training environment for students and postdoctoral fellows, strengthen the coronavirus antiviral drug discovery pipeline, highlight existing expertise, infrastructure and services available to scientists through the API to advance their research.

EDMONTON, Alta., March 31, 2022 /CNW/ – Applied Pharmaceutical Innovation (API)a non-profit life science organization has partnered with a team of researchers from Dalhousie University and Mount Saint Vincent University in Nova Scotia conduct research to understand the antiviral mechanism of the FDA-approved thiopurine drug named 6-thioguanine (6-TG). The researchers and API plan to use this information to develop new chemical entities with greater specificity and potency that can be used to improve antiviral drug discovery against SARS-CoV-2 and other viruses. RNA.

Applied Pharmaceutical Innovation (API) announces the creation of a team with researchers from has partnered with a team of researchers from Dalhousie University and Mount Saint Vincent University in Nova Scotia for drug discovery antiviral against SARS-CoV-2 and RNA viruses (CNW Group/Applied Innovation Pharmaceuticals)

dr. Craig McCormickMicrobiology and Immunology, Dalhousie Universitydr. Sultan Darveshmedicine and medical neurosciences, Dalhousie Universityand dr. ian pottieChemistry and Physics, Mount Saint Vincent University are the main contributors to this study with the support of experts from API and its network facilities.

In addition to providing researchers with access to expertise and infrastructure, the project will involve API employing a team at Dalhousie. This will create opportunities for trainees and postdoctoral fellows to improve their technical and scientific skills in antiviral drug research and to become highly qualified professionals (HQP) with career prospects with API, academia and the life sciences industry.

“Further research on the existing drug Thioguanine (6-TG) will help us understand its targets and mechanism, and eventually find more promising and improved antivirals to use in any future pandemic scenario. We are delighted to have API as an industry partner for this study. Industry collaborations like these open doors for more innovative research to continue in Canadaand the development of translational teams and HQP that can facilitate more research in the life sciences,” said dr. Craig McCormickMicrobiology and Immunology, Dalhousie University.

“Collaborations like these between academia and industry across all provinces are key to building a more vibrant and integrated life sciences ecosystem,” noted Andrew MacIsaacCEO, API. “At API, our goal is to catalyze innovative research ideas from academic institutions and give them the tools and expertise they need to create potential drugs and therapies. This collaboration will also add to the antiviral drug discovery pipeline, strengthening from Canada pandemic preparedness against viruses like COVID-19. »

About the API
Applied Pharmaceutical Innovation (API) is a not-for-profit institute impacting the life sciences by bridging the gap between academia and industry. With a network of over 100 pharmaceutical scientists, clinicians, regulatory, patent and market experts, API brings vital research to the real world. API has an interdisciplinary team of experts who work with collaborating organizations to provide the expertise, services and infrastructure of a pharmaceutical company. The API helps innovators take their ideas to the real world, connects industry to the translational science they need to succeed, and accelerates all aspects of the drug development process.

SOURCE Applied Pharmaceutical Innovation

Quote

Quote

Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2022/31/c3100.html